POCT Cardiac
[POCT Cardiac]
EPTIS Ringversuch Nr. 1176672 | Letze Änderung 2024-05-22 | URL: https://www.eptis.bam.de/pts1176672 https://www.eptis.bam.de/pts1176672
| Name des Anbieters | |||||||||||||||||||
| Name des Anbieters | Weqas Weqas | ||||||||||||||||||
| Ansässig in | United Kingdom | ||||||||||||||||||
| Sprache(n) | |||||||||||||||||||
| Anmerkungen | Three liquid human plasma samples are distributed monthly, with a minimum of 36 samples distributed over the year covering a wide clinical range. The samples consist of a panel of linearly related samples produced from heparin plasma donations from healthy volunteers spiked with Cardiac Troponin complex, Myoglobin, and the MB isoenzyme of Creatine Kinase (CKMB). The programme includes samples that span the analytical and clinically relevant ranges. The programme accommodates POCT assays reporting quantitative and qualitative results. They are distributed on a number of occasions over the year, which allows for the assessment of the organisation’s and method’s performance, including linearity, bias, within and between batch imprecision. Key Features: - EDTA plasma samples require no pre-analytical preparation. - Linearly related panel covering a clinically relevant range. For more information: https://www.weqas.com/services/poct-eqa/poct-cardiac/ or contact@weqas.com For information on hsTroponin https://www.weqas.com/services/eqa/hs-troponin/ or contact@weqas.com | ||||||||||||||||||
| Klassifizierung | |||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
||||||||||||||||||
| Technische Einzelheiten | |||||||||||||||||||
|
|||||||||||||||||||
| Ringversuchsziele | |||||||||||||||||||
| Zielgruppe des Ringversuchs | The Programme aims to assess the performance of organisations utilising Point of Care tests (POCT) biochemical cardiac markers to aid in the assessment of acute coronary syndrome (ACS) and cardiac ischaemia. A separate programme is available for High sensitivity cardiac Troponin T and I. | ||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS based on ISO/IEC 17043. | ||||||||||||||||||
| Weitere Ziele | validation of testing methods | ||||||||||||||||||
| Teilnehmerzahl | |||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 nicht für alle Parameter |
||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||||||||||||||
| Kosten | |||||||||||||||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | ||||||||||||||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 3 x 0.5mL. ) | ||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 2005 | ||||||||||||||||||
| Kontaktdaten des Anbieters | |||||||||||||||||||
| Anbieter | Kontaktperson | ||||||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.